193 related articles for article (PubMed ID: 31955214)
1. In the South African setting, HIV-associated Burkitt lymphoma is associated with frequent leukaemic presentation, complex cytogenetic karyotypes, and adverse clinical outcomes.
Opie J; Antel K; Koller A; Novitzky N
Ann Hematol; 2020 Mar; 99(3):571-578. PubMed ID: 31955214
[TBL] [Abstract][Full Text] [Related]
2. Low incidence of MYC/BCL2 double-hit in Burkitt lymphoma.
Yoshida M; Ichikawa A; Miyoshi H; Kiyasu J; Kimura Y; Niino D; Ohshima K
Pathol Int; 2015 Sep; 65(9):486-9. PubMed ID: 26182827
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
[TBL] [Abstract][Full Text] [Related]
4. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
[TBL] [Abstract][Full Text] [Related]
5. Burkitt leukaemia/lymphoma: R-CODOX-M/R-IVAC remains gold standard treatment in BL.
Smyth L; Browne PV; Conneally E; Flynn C; Hayden P; Jeffers M; O'Brien D; Quinn F; Kelly J; Perera M; Crotty GM; Leahy M; Hennessy B; Jackson F; Ryan M; Vandenberghe E
Ir J Med Sci; 2016 Nov; 185(4):773-777. PubMed ID: 25843016
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Characterization of Children With B-Cell Non-Hodgkin Lymphoma Over 10 Years at a Tertiary Center in Cape Town, South Africa.
Kriel M; Davidson A; Pillay K; Hendricks M; Phillips LA
J Pediatr Hematol Oncol; 2020 May; 42(4):e219-e227. PubMed ID: 32332383
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin's lymphomas with Burkitt-like cells are associated with c-Myc amplification and poor prognosis.
Mossafa H; Damotte D; Jenabian A; Delarue R; Vincenneau A; Amouroux I; Jeandel R; Khoury E; Martelli JM; Samson T; Tapia S; Flandrin G; Troussard X
Leuk Lymphoma; 2006 Sep; 47(9):1885-93. PubMed ID: 17065002
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of HIV-associated Burkitt Lymphoma in Brazil: High treatment toxicity and refractoriness rates - A multicenter cohort study.
Silva WFD; Garibaldi PMM; Rosa LID; Bellesso M; Clé DV; Delamain MT; Rego EM; Pereira J; Rocha V
Leuk Res; 2020 Feb; 89():106287. PubMed ID: 31864677
[TBL] [Abstract][Full Text] [Related]
9. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
[TBL] [Abstract][Full Text] [Related]
10. Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers.
Evens AM; Danilov A; Jagadeesh D; Sperling A; Kim SH; Vaca R; Wei C; Rector D; Sundaram S; Reddy N; Lin Y; Farooq U; D'Angelo C; Bond DA; Berg S; Churnetski MC; Godara A; Khan N; Choi YK; Yazdy M; Rabinovich E; Varma G; Karmali R; Mian A; Savani M; Burkart M; Martin P; Ren A; Chauhan A; Diefenbach C; Straker-Edwards A; Klein AK; Blum KA; Boughan KM; Smith SE; Haverkos BM; Orellana-Noia VM; Kenkre VP; Zayac A; Ramdial J; Maliske SM; Epperla N; Venugopal P; Feldman TA; Smith SD; Stadnik A; David KA; Naik S; Lossos IS; Lunning MA; Caimi P; Kamdar M; Palmisiano N; Bachanova V; Portell CA; Phillips T; Olszewski AJ; Alderuccio JP
Blood; 2021 Jan; 137(3):374-386. PubMed ID: 32663292
[TBL] [Abstract][Full Text] [Related]
11. Patterns of genomic aberrations suggest that Burkitt lymphomas with complex karyotype are distinct from other aggressive B-cell lymphomas with MYC rearrangement.
Havelange V; Ameye G; Théate I; Callet-Bauchu E; Mugneret F; Michaux L; Dastugue N; Penther D; Barin C; Collonge-Rame MA; Baranger L; Terré C; Nadal N; Lippert E; Laï JL; Cabrol C; Tigaud I; Herens C; Hagemeijer A; Raphael M; Libouton JM; Poirel HA;
Genes Chromosomes Cancer; 2013 Jan; 52(1):81-92. PubMed ID: 23012230
[TBL] [Abstract][Full Text] [Related]
12. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
[TBL] [Abstract][Full Text] [Related]
13. Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia.
Park YH; Kim WS; Kang HJ; Na II; Ryoo BY; Yang SH; Lee SS; Uhm JE; Kim K; Jung CW; Park K; Ko YH
Ann Hematol; 2006 May; 85(5):285-90. PubMed ID: 16518604
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.
Preudhomme C; Dervite I; Wattel E; Vanrumbeke M; Flactif M; Lai JL; Hecquet B; Coppin MC; Nelken B; Gosselin B
J Clin Oncol; 1995 Apr; 13(4):812-20. PubMed ID: 7707106
[TBL] [Abstract][Full Text] [Related]
15. Small noncleaved, non-Burkitt's (Burkit-Like) lymphoma: cytogenetics predict outcome and reflect clinical presentation.
Macpherson N; Lesack D; Klasa R; Horsman D; Connors JM; Barnett M; Gascoyne RD
J Clin Oncol; 1999 May; 17(5):1558-67. PubMed ID: 10334544
[TBL] [Abstract][Full Text] [Related]
16. Burkitt's lymphoma in adults with and without human immunodeficiency virus infection: a single-institution clinicopathologic study of 75 patients.
Spina M; Tirelli U; Zagonel V; Gloghini A; Volpe R; Babare R; Abbruzzese L; Talamini R; Vaccher E; Carbone A
Cancer; 1998 Feb; 82(4):766-74. PubMed ID: 9477111
[TBL] [Abstract][Full Text] [Related]
17. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
[TBL] [Abstract][Full Text] [Related]
18. Real-world outcomes of AIDS-related Burkitt lymphoma: a retrospective study of 78 cases over a 10-year period.
Wang Z; Zhang R; Gong Z; Liu L; Shen Y; Chen J; Qi T; Song W; Tang Y; Sun J; Lin Y; Xu S; Yang J; Lu H
Int J Hematol; 2021 Jun; 113(6):903-909. PubMed ID: 33594656
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
[TBL] [Abstract][Full Text] [Related]
20. Chromosomal abnormalities in adult non-endemic Burkitt's lymphoma and leukemia: 22 new reports and a review of 148 cases from the literature.
Kornblau SM; Goodacre A; Cabanillas F
Hematol Oncol; 1991; 9(2):63-78. PubMed ID: 1869243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
